Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2
Alzinova AB (publ) (“Alzinova” or “the Company”) announces today that the Company has successfully verified that the manufacturing process for vaccine doses of ALZ-101, the Company’s vaccine candidate against Alzheimer’s disease, can be scaled up to deliver larger production volumes required for clinical phase 2 trials.Preparations for clinical phase 2 development are progressing successfully and the Company has now verified that the manufacturing process can produce larger volumes of Alzinova's Alzheimer's vaccine candidate ALZ-101. Earlier this year, Alzinova announced that it had already